Peoples Bank OH Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Peoples Bank OH grew its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 0.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,383 shares of the company’s stock after purchasing an additional 20 shares during the quarter. Eli Lilly and Company makes up about 1.0% of Peoples Bank OH’s holdings, making the stock its 23rd largest position. Peoples Bank OH’s holdings in Eli Lilly and Company were worth $1,854,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in LLY. Proficio Capital Partners LLC increased its holdings in shares of Eli Lilly and Company by 1.7% in the 1st quarter. Proficio Capital Partners LLC now owns 6,511 shares of the company’s stock valued at $5,063,000 after acquiring an additional 106 shares during the period. Lorne Steinberg Wealth Management Inc. grew its position in Eli Lilly and Company by 3.9% during the 1st quarter. Lorne Steinberg Wealth Management Inc. now owns 431 shares of the company’s stock worth $335,000 after purchasing an additional 16 shares during the last quarter. Central Pacific Bank Trust Division acquired a new position in Eli Lilly and Company in the first quarter valued at $9,194,000. Whittier Trust Co. of Nevada Inc. increased its stake in Eli Lilly and Company by 155.1% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 19,745 shares of the company’s stock valued at $15,361,000 after purchasing an additional 12,004 shares during the period. Finally, Whittier Trust Co. raised its holdings in shares of Eli Lilly and Company by 52.2% in the first quarter. Whittier Trust Co. now owns 75,487 shares of the company’s stock valued at $58,725,000 after buying an additional 25,877 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $5.02 during trading on Wednesday, hitting $937.52. 696,411 shares of the stock were exchanged, compared to its average volume of 2,921,544. The company has a market cap of $891.03 billion, a PE ratio of 137.46, a P/E/G ratio of 2.00 and a beta of 0.41. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company has a fifty day moving average price of $838.34 and a two-hundred day moving average price of $757.52. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $939.98.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.62 earnings per share. On average, analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. Eli Lilly and Company’s payout ratio is 76.58%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LLY. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, July 1st. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Argus boosted their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, BMO Capital Markets restated an “outperform” rating and set a $1,001.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, July 3rd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $816.78.

View Our Latest Stock Report on LLY

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 93,593 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $918.64, for a total value of $85,978,273.52. Following the sale, the insider now directly owns 97,153,810 shares in the company, valued at $89,249,376,018.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 93,593 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $918.64, for a total value of $85,978,273.52. Following the completion of the transaction, the insider now directly owns 97,153,810 shares of the company’s stock, valued at $89,249,376,018.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. In the last three months, insiders sold 1,004,704 shares of company stock worth $869,479,116. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.